Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [18F]FPWAY

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 389-393

  Ma, Ying ^a   Lang, Lixin ^a   Reyes, Larry ^a   Tokugawa, Joji ^a   Jagoda, Elaine M ^a   Kiesewetter, Dale O ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

5 HT1A, Metabolites; Biodistribution; FPWAY; LC MS; PET radiotracer

Indexed keywords

[4 FLUORO N [2 [4 (2 METHOXY PHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIMIDINYL)BENZAMIDE] F 18; RADIOPHARMACEUTICAL AGENT; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; ULTRAPERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; LIGANDS; MALE; MASS SPECTROMETRY; ORGAN SPECIFICITY; PIPERAZINES; PYRIMIDINES; RADIOACTIVE TRACERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 67349284059     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.002     Document Type: Article

References (18)

1. Phelps M.E. PET: physics, instrumentation and scanners (2006), Springer, New York
2. Welch M.J., and Redvanly C.S. Handbook of Radiopharmaceuticals. 1st ed. (2002), Wiley, New York
3. Stöcklin G., and Pike V.W. Radiopharmaceuticals for positron emission tomography - methodological aspects. 1st ed. (1993), Kluwer Acedemic Press, Dordrecht, Netherlands
4. Giovacchini G., Lang L., Ma Y., Herscovitch P., Eckelman W., and Carson R.E. Differential effects of the selective serotonin reuptake inhibitor paroxetine on raphe and cortical 5-HT1A binding; A PET study in monkey with [18F]FPWAY. Neuroimage 22 Suppl 2 (2004) T25-T26
5. Lang L., Jagoda E., Schmall B., Sassaman M., Ma Y., et al. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. Nucl Med Biol 27 (2000) 457-462
6. Lang L., Jagoda E., Schmall B., Sassaman M., Ma Y., and Eckelman W.C. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. Nucl Med Biol 27 5 (2000) 457-462
7. Fletcher A., Clif I.A., and Dourish C.T. Silent 5-TH1A receptor antagonist: utility as research and therapeutic agents. TIPS 141 (1993) 441-448
8. Ma Y., Kiesewetter D., Lang L., and Eckelman W.C. Application of LC-MS to the analysis of new radiopharmaceuticals. Mol Imaging Biol 5 6 (2003) 397-403
9. 1A receptor antagonists, 3-trans and 3-cis-FCWAY. Nucl Med Biol 33 (2006) 1013-1019
10. Matusch A., Meyer P., Bier D., Holschbach M., Woitalla D., Elmenhorst D., et al. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl Med Biol 33 (2006) 891-898
11. 18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions. Nucl Med Biol 30 (2003) 235-240
12. Chernet E., Martin L.J., Li D., Need A.B., Barth V.N., Rash K.S., et al. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci 78 (2005) 340-346
13. Barth V.N., Chernet E., Martin L.J., Need A.B., Rash K.S., Morin M., et al. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci 78 (2006) 3007-3012
14. 1A receptors with positron emission tomography. Life Sci (1994) 403-407
15. 11C]WAY-100635. Eur J Pharmacol 283 (1995) R1-R3
16. Lang L., Jagoda E., Schmall B., Vuong B.K., Adams H.R., et al. The development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem 42 (1999) 1576-1586
17. Carson R.E., Lang L., Watabe H., Der M.G., Adams H.R., et al. PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl Med Biol 27 (2000) 493-497
18. Lang L., Jagoda E., Ma Y., Sassaman M.B., and Eckelman W.C. Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans fluorocyclohexane derivatives of WAY 100635. Bioorg Med Chem 14 (2006) 3737-3748